Project cooperationUpdated on 13 August 2025
Looking for Clinical trial of early diagnosis of kidney damage in patients
About
How it Works?
The solution is used in conjunction with common urine glucose measurement kits to determine trehalase activity, a key marker of kidney function. By analyzing this specific enzyme, Nephrotest helps healthcare professionals identify potential acute kidney injury at an early stage. This is particularly useful for hospitalized and intensive care patients, where early detection can lead to timely intervention and improved outcomes.
Why is Argeron Nephrotest Important?
-
Early & Accurate Detection: Unlike some traditional tests, Nephrotest provides a rapid, widespread, and economical method for the early identification of kidney damage, even before symptoms become apparent.
-
Effective Monitoring: It allows for the regular monitoring of patients with risk factors, enabling more proactive and effective management of kidney health.
-
Patient Safety: By helping to detect adverse effects of medications or complications from other diseases, it plays a significant role in patient safety and reducing healthcare costs associated with advanced kidney failure.
Stage
- Execution
Topic
- Biotechnology
Type
- Research
Organisation
Argeron Medikal Araştırma Sanayi ve Ticaret A.Ş.
Antalya, Türkiye
Similar opportunities
Partnership
Early detection of kidney injury
- Technology Transfer
- Research and Development
- Technology Trials / Testing
Bülent BIDI
CEO at Argeron Medikal Araştırma Sanayi ve Ticaret A.Ş.
Antalya, Türkiye
Expertise
Advanced Medical and Biotechnology Solutions Medical Research and Diagnostic Development
- Healthcare
- Biotech, Pharma and Cosmetics
- Food, Beverages and Agriculture
Bülent BIDI
CEO at Argeron Medikal Araştırma Sanayi ve Ticaret A.Ş.
Antalya, Türkiye
Partnership
Argeron Magnetic Auto Injector
- Technology Transfer
Bülent BIDI
CEO at Argeron Medikal Araştırma Sanayi ve Ticaret A.Ş.
Antalya, Türkiye